Institution
The Barbara Ann Karmanos Cancer Institute
Also known as: Barbara Ann Karmanos Cancer Center · Barbara Ann Karmanos Cancer Institute · Barbara Ann Karmanos Comprehensive Cancer Center · Barbara Ann Karmanos Comprehensive Cancer Institute · Karmanos Cancer Center · Karmanos Cancer Hospital
- 378running trials
- 195closed trials
- 1researcher
- 12,358publications (OpenAlex)
Researchers
Running trials
Not yet recruiting
MyPatientPal+: A Smartphone App and a Provider Dashboard to Manage Patient Care While on Treatment
Not yet recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting
Recruiting
A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Recruiting
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
Enrolling by invitation
Recruiting
Recruiting
Recruiting
Recruiting
First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Recruiting
Recruiting
Recruiting
Recruiting
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Recruiting
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Recruiting
Recruiting
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Recruiting
Recruiting
Showing 50 of 378.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Ovarian cancer24 recruiting
- Lung cancer20 recruiting
- Endometrial cancer15 recruiting
- Head and neck cancer15 recruiting
- Prostate cancer12 recruiting
- Colorectal cancer11 recruiting
- Pancreatic cancer11 recruiting
- Bladder cancer10 recruiting
- Multiple myeloma10 recruiting
- Gastric and oesophageal cancer8 recruiting
- Liver and biliary tract cancer8 recruiting
- Triple-negative breast cancer8 recruiting
- Metastatic breast cancer6 recruiting
- Acute myeloid leukaemia5 recruiting
- Chronic lymphocytic leukaemia5 recruiting
- Amyloidosis4 recruiting
- Follicular lymphoma4 recruiting
- Childhood cancers3 recruiting
- Diffuse large B-cell lymphoma3 recruiting
- Myelodysplastic syndromes3 recruiting
- Myeloproliferative neoplasms3 recruiting
- Acute lymphoblastic leukaemia2 recruiting
- Cervical cancer2 recruiting
- Chronic myeloid leukaemia2 recruiting
- Mantle cell lymphoma2 recruiting
- Melanoma2 recruiting
- Neuroendocrine tumours2 recruiting
- Sarcoma2 recruiting
- Aplastic anaemia1 recruiting
- Brain metastases1 recruiting
- Glioblastoma1 recruiting
- Meningioma1 recruiting
- Mesothelioma1 recruiting
- Myasthenia gravis1 recruiting
- Testicular cancer1 recruiting
Closed trials
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Terminated
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Terminated
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Recruiting
Terminated
Recruiting
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Completed
Completed
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
Completed
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Recruiting
Terminated
Recruiting
Terminated
Terminated
Terminated
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Terminated
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Withdrawn
Recruiting
Terminated
Terminated
Terminated
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
Recruiting
Recruiting
Terminated
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Withdrawn
Completed
Terminated
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Completed
Terminated
Completed
Terminated
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma
Terminated
Completed
Withdrawn
Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant
Terminated
Terminated
Terminated
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Completed
Completed
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Completed
Terminated
Terminated
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
Completed
Recruiting
Completed
Terminated
Recruiting
Completed
Completed
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
Showing 50 of 195.
Registry name variants (38)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
241 trials
Karmanos Cancer Institute
Detroit, Michigan 48201
196 trials
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan 48201
74 trials
Karmanos Cancer Center
Detroit, Michigan 48201
22 trials
Barbara Ann Karmanos Cancer Center
Detroit, Michigan 48201
5 trials
Wayne State - Karmanos Cancer Institute
Detroit, Michigan 48201
4 trials
Karmanos Cancer Institute
Farmington Hills, Michigan 48334
2 trials
Karmanos Cancer Institute (Site 0018)
Detroit, Michigan 48201
2 trials
Karmanos Cancer Institute - Wayne State University
Detroit, Michigan 48201
2 trials
The Barbara Ann Karmanos Cancer Institute
Detroit, Michigan 48201
2 trials
NCT05651022Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Contact: Sharon Prokop
Barbara Ann Karmanos Cancer Institute
Lansing, Michigan 48910
1 trial
Barbara Ann Karmanos Cancer Institute - Detroit
Detroit, Michigan 48201
1 trial
Contact: Clinical Trials Administrator
Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute (Site 0041)
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute (Site 0046)
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute (Site 0077)
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute (Site 0272)
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute (Site 1566)
Detroit, Michigan 48201
1 trial
Barbara Ann Karmanos Cancer Institute (Site 1785)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Center (Site 109)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute - Detroit
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute - Detroit
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute - Detroit
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute - Detroit
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute - Detroit
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute - Detroit- Site Number : 8400013
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0002)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0013)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0029)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0033)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0054)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0111)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0174)
Detroit, Michigan 48201
1 trial
Contact: Study Coordinator
Karmanos Cancer Institute (Site 0216)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 0712)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 1007)
Detroit, Michigan 48201
1 trial
Karmanos Cancer Institute (Site 1870)
Detroit, Michigan 48201
1 trial
Conditions
Diseases this institution publishes on or runs trials for.
- Endometrial cancer13 works · 36 trials
Institution data: ROR 00ee40h97 (CC0-1.0)Updated 15 Nov 2026